These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 25904370

  • 1. Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-Optimal Protection Against Respiratory Syncytial Virus.
    Weinberger DM, Warren JL, Steiner CA, Charu V, Viboud C, Pitzer VE.
    Clin Infect Dis; 2015 Aug 15; 61(4):506-14. PubMed ID: 25904370
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.
    Gutfraind A, Galvani AP, Meyers LA.
    JAMA Pediatr; 2015 Apr 15; 169(4):341-8. PubMed ID: 25706618
    [Abstract] [Full Text] [Related]

  • 3. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD.
    J Manag Care Pharm; 2010 Apr 15; 16(1):15-22. PubMed ID: 20044843
    [Abstract] [Full Text] [Related]

  • 4. Editorial Commentary: Can a Reduced-Dose Prophylaxis Schedule Provide Adequate Coverage Against Respiratory Syncytial Virus Infection?
    Panozzo CA, Hampp C.
    Clin Infect Dis; 2015 Aug 15; 61(4):515-6. PubMed ID: 25904371
    [No Abstract] [Full Text] [Related]

  • 5. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
    Narayan O, Bentley A, Mowbray K, Hermansson M, Pivonka D, Kemadjou EN, Belsey J.
    J Med Econ; 2020 Dec 15; 23(12):1640-1652. PubMed ID: 33107769
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep 15; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D, Bayliss S, Meads C.
    Health Technol Assess; 2011 Jan 15; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom.
    Goddard NL, Cooke MC, Gupta RK, Nguyen-Van-Tam JS.
    Epidemiol Infect; 2007 Jan 15; 135(1):159-62. PubMed ID: 16753078
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, IRIS Study Group.
    Pediatr Infect Dis J; 2003 Sep 15; 22(9):823-7. PubMed ID: 14506376
    [Abstract] [Full Text] [Related]

  • 15. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM.
    Arch Pediatr Adolesc Med; 2000 Jan 15; 154(1):55-61. PubMed ID: 10632251
    [Abstract] [Full Text] [Related]

  • 16. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
    Diehl JL, Daw JR, Coley KC, Rayburg R.
    J Manag Care Pharm; 2010 Jan 15; 16(1):23-31. PubMed ID: 20044844
    [Abstract] [Full Text] [Related]

  • 17. Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus.
    Makari D, Checchia PA, Devincenzo J.
    Hum Vaccin Immunother; 2014 Jan 15; 10(3):607-14. PubMed ID: 24316863
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD.
    Pediatr Infect Dis J; 2012 Jan 15; 31(1):e1-8. PubMed ID: 21960187
    [Abstract] [Full Text] [Related]

  • 19. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI, Lanctôt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P, Composs Investigators.
    Pediatr Infect Dis J; 2002 Jun 15; 21(6):512-8. PubMed ID: 12182374
    [Abstract] [Full Text] [Related]

  • 20. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR.
    Pediatr Infect Dis J; 2003 Feb 15; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.